The Impact of GLP-1 Medications on Life Insurance Underwriting
Discover the impact of GLP-1 medications on life insurance underwriting and health outcomes, highlighting AI's role in improving predictions and insurer operations.
CMS Proposes Voluntary Medicaid and Medicare GLP-1 Coverage Trial
CMS plans a voluntary five-year trial allowing state Medicaid and Medicare Part D plans to cover GLP-1 weight management drugs, including Ozempic and Wegovy, starting in 2026-27 amid pricing and coverage challenges.
Medicare Weight Loss Drug Coverage: Legislative and Regulatory Paths
Medicare faces evolving opportunities and challenges in covering weight loss drugs through legislation like the Treat and Reduce Obesity Act and federal demonstration projects. Drug adherence and cost-effectiveness remain key issues.
Celebrity Weight Loss Stories Highlight Trends in Aging and Insurance Risk
Celebrity health journeys reveal critical insights into obesity risks, chronic disease management, and insurance implications for older Americans.
Bipartisan Bill Proposes Expanded Medicare Coverage for Obesity Treatment
The Treat and Reduce Obesity Act introduces expanded Medicare coverage for obesity screenings, specialists, and medications, aiming to reduce obesity-related diseases and healthcare costs among seniors.
CMS Excludes Obesity Drugs from Medicare Coverage Amid Cost Concerns
CMS excludes obesity drugs from 2026 Medicare coverage, citing cost concerns; Eli Lilly criticizes the decision impacting obesity management treatments.
Medicare Coverage for Anti-Obesity Drugs Gains Attention in Maine
Maine advocates seek Medicare coverage for anti-obesity medications to improve public health, reduce healthcare costs, and promote active transportation. Bipartisan support grows with Senator Susan Collins' leadership.